文献速递皮肤肿瘤

烟酰胺用于皮肤癌化学预防

Nicotinamide for Skin Cancer Chemoprevention.
PubMed 文献 · JAMA Dermatol · 2025-01-01

倾向性评分匹配后分析显示,烟酰胺暴露与皮肤癌风险显著降低14%相关,首次皮肤癌后启动治疗风险降低达54%,但获益随后续皮肤癌次数增加而下降。在实体器官移植受者中未观察到总体显著风险降低,但早期使用与皮肤鳞状细胞癌发生率降低相关。

要点

  • 烟酰胺500mg每日两次与皮肤癌总体风险降低14%相关。
  • 首次皮肤癌后启动烟酰胺风险降低54%,但后续皮肤癌后启动获益下降。
  • 实体器官移植受者总体风险降低不显著,早期使用或降低cSCC。

核心结论

  • 烟酰胺治疗与皮肤癌风险降低相关,首次皮肤癌后启动效果最明显。
  • 实体器官移植受者总体风险降低不显著,但早期使用与cSCC发生率降低相关。

研究设计与样本

  • 回顾性队列研究,使用美国退伍军人事务部电子健康记录数据(1999年10月1日至2024年12月31日)。
  • 暴露定义为口服烟酰胺500mg每日两次持续超过30天。
  • 主要结局为基线后至下一次皮肤癌的时间,采用分层Cox模型分析。

主要发现

  • 匹配队列中实体器官移植受者1334例(3.9%)。
  • 总体皮肤癌风险显著降低14%。
  • 首次皮肤癌后启动烟酰胺风险降低54%,但后续皮肤癌后启动获益下降。
  • 风险降低见于总体皮肤癌、基底细胞癌和cSCC,其中cSCC降低最明显。

临床怎么用

  • 对于有皮肤癌病史的患者,尤其是首次皮肤癌后,可考虑使用烟酰胺500mg每日两次进行化学预防。
  • 在实体器官移植受者中,烟酰胺的总体获益不显著,早期使用可能对cSCC有预防作用。

局限性

  • 回顾性队列研究设计可能存在残余混杂。
  • 研究人群以白人老年男性为主,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nicotinamide supplementation has been studied as a chemopreventive medication for reducing skin cancer risk, but large-scale data are limited. OBJECTIVE: To determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted using electronic health record data (October 1, 1999, to December 31, 2024) from the Veterans Affairs Corporate Data Warehouse (CDW) of 33 822 patients. Analyses were conducted from January 17, 2025, to May 9, 2025. Patients who were exposed to nicotinamide were propensity score matched based on the number and year of skin cancers after which treatment with nicotinamide was initiated, age, sex, self-reported race, exposure to acitretin, exposure to field therapy, history of chronic lymphocytic leukemia, and history of solid organ transplant. The index date was the first prescription of nicotinamide filled within the VA system. Stratified Cox models were used to investigate the association of nicotinamide with skin cancer development. EXPOSURES: Nicotinamide, 500 mg, twice daily for longer than 30 days as documented in the electronic health record. MAIN OUTCOMES AND MEASURES: Time to the next skin cancer after baseline. RESULTS: There were 12 287 patients (mean [SD] age, 77.2 [8.9] years; 241 women [2.0%]; 31 [0.3%] American Indian or Alaska Native, 3 [<0.1%] Asian, 13 [0.1%] Black or African American, 59 [0.5%] Native Hawaiian or other Pacific Islander, and 11 662 [94.9%] White individuals) exposed to oral nicotinamide, 500 mg, twice daily for longer than 30 days who were matched to 21 479 unexposed patients (mean [SD] age, 76.9 [8.7] years; 374 women [2.0%]; 49 [0.2%] American Indian or Alaska Native, 3 [<0.1%] Asian, 16 [0.1%] Black or African American, 88 [0.4%] Native Hawaiian or other Pacific Islander, and 20 517 [95.3%] White individuals). Within the matched dataset, there were 10 994 instances of basal cell carcinoma after nicotinamide exposure and 12 551 cutaneous squamous cell carcinoma (cSCC). A total of 1334 (3.9%) in the matched cohort were solid organ transplant recipients. Overall, there was a significant 14% reduction in skin cancer risk. When nicotinamide was initiated after a first skin cancer, the risk reduction rose to 54%, although this benefit declined with initiation following subsequent skin cancers. This risk reduction was seen for skin cancers overall, basal cell carcinoma, and cSCC, with the greatest risk reduction seen for cSCC. Among solid organ transplant recipients, no overall significant risk reduction was observed, although early nicotinamide use was associated with reduced cSCC incidence. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that there is a decreased risk of skin cancer among patients treated with nicotinamide, with the greatest effect seen when initiated after the first skin cancer.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Breglio KF, Knox KM, Hwang J, et al. Nicotinamide for Skin Cancer Chemoprevention. JAMA Dermatol. 2025. PMID: 40960808. doi:10.1001/jamadermatol.2025.3238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。